The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With Diabetes
Open accessAbstract
Purpose: To evaluate the association between cumulative duration of metformin use after prostate cancer (PC) diagnosis and all-cause and PC-specific mortality among patients with diabetes. Patients and Methods: We used a population-based retrospective cohort design. Data were obtained from several Ontario health care administrative databases. Within a cohort of men older than age 66 years with incident diabetes who subsequently developed PC, we examined the effect of duration of antidiabetic medication exposure after PC diagnosis on all-cause and PC-specific mortality. Crude and adjusted hazard ratios (HRs) were calculated by using a time-varying Cox proportional hazard model to estimate effects. Results: The cohort consisted of 3,837 patients. Median age at diagnosis of PC was 75 years (interquartile range [IQR], 72 to 79 years). During a median follow-up of 4.64 years (IQR, 2.7 to 7.1 years), 1,343 (35%) died, and 291 patients (7.6%) died as a result of PC. Cumulative duration of metformin treatment after PC diagnosis was associated with a significant decreased risk of PC-specific and all-cause mortality in a dose-dependent fashion. Adjusted HR for PC-specific mortality was 0.76 (95% CI, 0.64 to 0.89) for each additional 6 months of metformin use. The association with all-cause mortality was also significant but declined over time from an HR of 0.76 in the first 6 months to 0.93 between 24 and 30 months. There was no relationship between cumulative use of other antidiabetic drugs and either outcome. Conclusion: Increased cumulative duration of metformin exposure after PC diagnosis was associated with decreases in both all-cause and PC-specific mortality among diabetic men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
The environment and disease: association or causation?
Hill, A. B. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814562718 · Cited by 7,285
Siegel, R., Ward, E., Brawley, O., & Jemal, A. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20121 · Cited by 4,070
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Dichotomizing continuous predictors in multiple regression: a bad idea
Royston, P., Altman, D. G., & Sauerbrei, W. (2006) · Statistics in Medicine · doi:10.1002/sim.2331 · Cited by 2,312
Regression Using Fractional Polynomials of Continuous Covariates: Parsimonious Parametric Modelling
Royston, P., & Altman, D. G. (1994) · Applied Statistics · doi:10.2307/2986270 · Cited by 1,798
Hux, J. E., Ivis, F., Flintoft, V., & Bica, A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.512 · Cited by 1,290
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Statin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880
Statin Use and Reduced Cancer-Related Mortality
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1214827 · Cited by 720
Shrank, W. H., Patrick, A. R., & Alan Brookhart, M. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1609-1 · Cited by 630
Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy
Braga-Basaria, M., Dobs, A. S., Muller, D. C., Carducci, M. A., John, M., Egan, J., & Basaria, S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9741 · Cited by 585
An application of capture-recapture methods to the estimation of completeness of cancer registration
Robles, S. C., Marrett, L. D., Aileen Clarke, E., & Risch, H. A. (1988) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(88)90052-2 · Cited by 582
(2003) · PubMed · Cited by 490
Statin Drugs and Risk of Advanced Prostate Cancer
Platz, E. A., Leitzmann, M. F., Visvanathan, K., Rimm, E. B., Stampfer, M. J., Willett, W. C., & Giovannucci, E. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj499 · Cited by 406
Austin, P. C., van Walraven, C., Wodchis, W. P., Newman, A., & Anderson, G. M. (2011) · Medical Care · doi:10.1097/mlr.0b013e318215d5e2 · Cited by 326
Self-citationMetformin for the treatment of the polycystic ovary syndrome
Nestler, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0707092 · Cited by 313
Metformin inhibits melanoma development through autophagy and apoptosis mechanisms
Tomic, T., Botton, T., Cerezo, M., Robert, G., Luciano, F., Puissant, A., Gounon, P., Allegra, M., Bertolotto, C., Bereder, J.-M., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.86 · Cited by 301
Wright, J. L., & Stanford, J. L. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9407-y · Cited by 276
Vazquez-Martin, A., Oliveras-Ferraros, C., & Menendez, J. A. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7499 · Cited by 250
Statin Adherence and Risk of Accidents: A Cautionary Tale
Dormuth, C. R., Patrick, A. R., Shrank, W. H., Wright, J. M., Glynn, R. J., Sutherland, J., & Brookhart, M. A. (2009) · Circulation · doi:10.1161/circulationaha.108.824151 · Cited by 244
Metformin and Other Biguanides in Oncology: Advancing the Research Agenda
Pollak, M. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0175 · Cited by 240
Austin, P. C., & Brunner, L. J. (2004) · Statistics in Medicine · doi:10.1002/sim.1687 · Cited by 240
Self-citationUsing cancer registry data for survival studies: the example of the Ontario Cancer Registry
Hall, S., Schulze, K., Groome, P., Mackillop, W., & Holowaty, E. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.05.001 · Cited by 181
Potshuma, W. F. M., Westendorp, R. G. J., & Vandenbroucke, J. P. (1994) · BMJ · doi:10.1136/bmj.308.6939.1268 · Cited by 162
He, X., Tu, S., Lee, M., & Yeung, S. J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr020 · Cited by 154
Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes
Azoulay, L., Dell’Aniello, S., Gagnon, B., Pollak, M., & Suissa, S. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0940 · Cited by 145
Stricker, B. H. C., & Stijnen, T. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9451-7 · Cited by 142
Nobes, J. P., Langley, S. E. M., Klopper, T., Russell-Jones, D. L., & Laing, R. W. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10555.x · Cited by 129
Longer Wait Times Increase Overall Mortality in Patients With Bladder Cancer
Kulkarni, G. S., Urbach, D. R., Austin, P. C., Fleshner, N. E., & Laupacis, A. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.06.041 · Cited by 123
Self-citationAntidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control Study
Murtola, T. J., Tammela, T. L. J., Lahtela, J. T., & Auvinen, A. P. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn190 · Cited by 107
Cuffe, S. D., Booth, C. M., Peng, Y., Darling, G. E., Li, G., Kong, W., Mackillop, W. J., & Shepherd, F. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3330 · Cited by 88
Pitfalls in Nonrandomized Outcomes Studies
Wen, S. W. (1995) · JAMA · doi:10.1001/jama.1995.03530210041028 · Cited by 69
Brenner, D. R., Tammemägi, M. C., Bull, S. B., Pinnaduwaje, D., & Andrulis, I. L. (2009) · Chronic diseases and injuries in Canada · doi:10.24095/hpcdp.30.1.04 · Cited by 63
Review article: the treatment of fatty liver disease associated with the metabolic syndrome
Marchesini, G., Natale, S., Manini, R., & Agostini, F. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02593.x · Cited by 20
Cited by
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
The Epidemiology of Prostate Cancer
Pernar, C. H., Ebot, E. M., Wilson, K. M., & Mucci, L. A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030361 · Cited by 773
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 452
Saraei, P., Asadi, I., Kakar, M. A., & Moradi-Kor, N. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200059 · Cited by 350
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Moon, Y. W., Hajjar, J., Hwu, P., & Naing, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0094-9 · Cited by 336
Metadata
- Authors
- Margel, D., Urbach, D. R., Lipscombe, L. L., Bell, C. M., Kulkarni, G., Austin, P. C., & Fleshner, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-09-01
- Volume
- 31
- Issue
- 25
- Pages
- 3069-3075
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2149179641
- Cited by
- 271
- References
- 37
- FWCI
- 17.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.